FDA
-
-
-
-
-
-
-
Cognition Therapeutics meets with FDA on DLB psychosis drug
-
-
-
-
-
-
-
Cognition Therapeutics reports 2025 loss of $23.5 million
-
-
-
-
-
-
-
Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
-
-
-
-
-
-
-
Cognition Therapeutics presents Phase 3 plan for alzheimer's drug
-
-
-
-
-
-
-
Cognition Therapeutics publishes zervimesine study data
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Cognition Therapeutics (CGTX)
-
-
-
-
-
-
-
Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences
-
325,143 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

